Sarcopenia

Decoding Sarcopenia: Advances in Research and Management: Dive into the evolving landscape of sarcopenia research. From cutting-edge studies on its impact on cancer patients to innovative management strategies, gain insights into combating this muscle-wasting condition.

A narrative review of sarcopenia in patients with cardiovascular kidney metabolic syndrome: Another brick in the wall?

Cardiovascular-kidney-metabolic syndrome (CKMS) is a recently launched by American Heart Association to express the importance of interplay among metabolic risk factors, chronic kidney disease, and the cardiovascular system which has profound impacts on morbidity and mortality. The common pathologic processes...

🗓️ 2026-05-13
📰 Publication: Clinical Nutrition
Read MoreA narrative review of sarcopenia in patients with cardiovascular kidney metabolic syndrome: Another brick in the wall?

Discovery of a Potent Antisarcopenia Drug Molecular Scaffold Derived from Ligusticum chuanxiong and Its Photochemical Synthesis.

Sarcopenia is a growing public health crisis with an unmet need for effective pharmacotherapies. Ligusticum chuanxiong (L. chuanxiong), commonly known as Chuanxiong in China, is a medicinal plant widely utilized for conditions involving muscle wasting and weakness. Herein, we report...

🗓️ 2026-05-11
📰 Publication: Journal Of The American Chemical Society
Read MoreDiscovery of a Potent Antisarcopenia Drug Molecular Scaffold Derived from Ligusticum chuanxiong and Its Photochemical Synthesis.

The diagnostic accuracy of blood biomarkers for sarcopenia, sarcopenic obesity, and osteosarcopenia: a meta-analysis.

BACKGROUND AND AIMS

Sarcopenia is the accelerated loss of skeletal muscle mass and function associated with ageing. Sarcopenia screening consists of body composition imaging and physical function tests; however, these tests can be burdensome and inconsistent. This review aimed to synthesise...

🗓️ 2026-05-11
📰 Publication: Archives Of Gerontology And Geriatrics
Read MoreThe diagnostic accuracy of blood biomarkers for sarcopenia, sarcopenic obesity, and osteosarcopenia: a meta-analysis.

Beyond the Lungs: The Role of Extrapulmonary Manifestations in the Quality of Life of Indians with Chronic Airway Diseases.

PURPOSE

Chronic airway diseases (CAD) including Chronic obstructive pulmonary diseases (COPD), persistent asthma (≥2weekly episodes) and bronchiectasis, exhibit overlapping extrapulmonary manifestations potentially affecting health-related quality-of-life (HRQOL). The study objective was to quantify HRQOL of CAD patients and identify impact of associated...

🗓️ 2026-05-09
📰 Publication: Respiratory Medicine
Read MoreBeyond the Lungs: The Role of Extrapulmonary Manifestations in the Quality of Life of Indians with Chronic Airway Diseases.

Sarcopenia, Grip Strength, Walking Pace, and New-Onset Stroke Risk: A UK Biobank Study.

BACKGROUND

Novel stroke risk factors have received widespread attention. This study examined the association between sarcopenia status, grip strength, and walking pace with incident stroke (any stroke, ischemic stroke, and hemorrhagic stroke) and poststroke mortality.

METHODS

This prospective study included 482 699 participants from...

🗓️ 2026-05-08
📰 Publication: Stroke
Read MoreSarcopenia, Grip Strength, Walking Pace, and New-Onset Stroke Risk: A UK Biobank Study.

The Association of Sarcopenic Obesity With Respiratory Function Outcomes in Adults: A Systematic Review and Meta-Analysis.

Sarcopenic obesity has been associated with various health conditions and mortality. Our objective was to systematically review and estimate the association between sarcopenic obesity and respiratory function outcomes. We searched EMBASE, MEDLINE, and Google Scholar for observational studies involving adults...

🗓️ 2026-05-08
📰 Publication: Obesity Reviews
Read MoreThe Association of Sarcopenic Obesity With Respiratory Function Outcomes in Adults: A Systematic Review and Meta-Analysis.

Effectiveness and Safety of Interventions for Sarcopenia in Advanced Prostate Carcinoma: Systematic Review.

BACKGROUND

Sarcopenia has emerged as a potential prognostic factor in patients with advanced prostate cancer (PCa), requiring interventions for its prevention and treatment.

OBJECTIVE

We aimed to systematically identify, critically assess and synthesize the available evidence on the effectiveness and safety of interventions...

🗓️ 2026-05-06
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreEffectiveness and Safety of Interventions for Sarcopenia in Advanced Prostate Carcinoma: Systematic Review.

Sarcopenia in Patients With Cancer and Its Association With Chemotherapy-Induced Peripheral Neurotoxicity.

BACKGROUND AND OBJECTIVES

Chemotherapy-induced peripheral neurotoxicity (CIPN) is the most common neurologic complication of cancer treatment. Sarcopenia, characterized by muscle mass loss, has been associated with treatment-related toxicity, but its association with CIPN remains unclear. We aimed to assess the association...

🗓️ 2026-05-05
📰 Publication: Neurology
Read MoreSarcopenia in Patients With Cancer and Its Association With Chemotherapy-Induced Peripheral Neurotoxicity.

Juyuanjian attenuates sarcopenia through dual regulation of the Akt/FoxO1 and SIRT1/PGC-1α pathways.

BACKGROUND

Sarcopenia, an age-related degenerative disease, corresponds to "Qi Xu" syndrome in traditional Chinese medicine. Juyuanjian (JYJ), a classical Qi-tonifying formula, has shown potential against muscle atrophy and functional decline, but its molecular mechanisms are not well understood.

PURPOSE

To investigate whether JYJ...

🗓️ 2026-05-03
📰 Publication: Phytomedicine
Read MoreJuyuanjian attenuates sarcopenia through dual regulation of the Akt/FoxO1 and SIRT1/PGC-1α pathways.

Elevated Circulating Ceramides 18:0 and 24:1 as a Risk Factor for Sarcopenia: In Vitro, Animal, and Clinical Evidence.

BACKGROUND

Ceramides have garnered considerable attention as pro-aging bioactive lipids implicated in both metabolic dysfunction and musculoskeletal decline. Among these, C18:0 and C24:1 ceramides may play a role in the pathophysiology of sarcopenia, a key manifestation of age-related deterioration. However, their...

🗓️ 2026-05-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreElevated Circulating Ceramides 18:0 and 24:1 as a Risk Factor for Sarcopenia: In Vitro, Animal, and Clinical Evidence.

Sarcopenia promotes tumorigenesis by disrupting NOTCH-SDC2-regulated biogenesis of muscle-derived extracellular vesicles.

Sarcopenia is an age-related condition characterized by loss of skeletal muscle mass and strength and is associated with increased cancer incidence and mortality, yet how muscle decline promotes tumorigenesis remains unclear. Here, we show that skeletal muscle functions as an...

🗓️ 2026-04-28
📰 Publication: Nature Communications
Read MoreSarcopenia promotes tumorigenesis by disrupting NOTCH-SDC2-regulated biogenesis of muscle-derived extracellular vesicles.

Simple clinical parameters to identify sarcopenia 1 year after gastrectomy for gastric cancer.

BACKGROUND

New-onset sarcopenia may develop after gastrectomy even in patients with normal muscle mass, but its detection in routine practice remains challenging. This study evaluated body composition changes after gastrectomy and identified clinical parameters associated with sarcopenia development.

METHODS

This retrospective study included...

🗓️ 2026-04-27
📰 Publication: Gastric Cancer
Read MoreSimple clinical parameters to identify sarcopenia 1 year after gastrectomy for gastric cancer.

Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology-Specific End-Stage Liver Disease.

BACKGROUND

Patients with end-stage liver disease (ESLD) often present with sarcopenia, defined as loss of skeletal muscle mass and quality, which is associated with reduced quality of life and increased mortality. However, the molecular mechanisms driving sarcopenia in ESLD are not...

🗓️ 2026-04-27
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSystemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology-Specific End-Stage Liver Disease.

Wearable Hybrid Strain-Myoelectric Sensing System for Machine-Learning-Assisted Sarcopenia Screening.

The early screening of sarcopenia represents a critical clinical need amid the accelerating global aging population. Current diagnostic methods, relying on bioelectrical impedance analysis (BIA), handgrip strength testing, and other clinical examinations, depend on costly medical equipment and struggle to...

🗓️ 2026-04-23
Read MoreWearable Hybrid Strain-Myoelectric Sensing System for Machine-Learning-Assisted Sarcopenia Screening.

SARCOPENIA DEFINITION

Sarcopenia is a condition which focuses on muscle loss. Loss of muscle mass and function, especially muscle strength and gait speed, associated with aging occurs in sarcopenia. Sarcopenia, cachexia, and malnutrition are considered as the main causes of muscle wasting and affect millions of elderly people and patients. Moreover, muscle atrophy can develop independently from diseases and age through disuse of the muscles. For a better classification and common language in medical science for ‘muscle wasting disease’ there is a proposal to combine the concepts of muscle wasting, sarcopenia, frailty, and cachexia by disease aetiology and disease progression. Patients with muscle atrophy show decreased muscle strength and therefore reduced quality of life, which is caused by a lower activity and increased exercise intolerance.

Despite a large number of studies, the understanding of the development of muscle wasting and the involved pathways remains very limited and more research is needed. Although many researchers and pharmaceutical companies have tried to find therapies for muscle atrophy, including cachexia and sarcopenia, no solution has been established until now.

REFERENCES

Rosenberg IH. Sarcopenia: origins and clinical relevance. Clin Geriatr Med 2011;27:337–339.

Anker SD, Coats AJ, Morley JE, Rosano G, Bernabei R, von Haehling S, Kalantar-Zadeh K. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle 2014;5:1–3

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!